Follow the Pundits
Tag: insider buying
📱 Thryv (THRY): Why John Paulson Just Bet Another $7.2 Million on This AI Turnaround
Thryv was once known for Yellow Pages directories. Today, roughly 76% of its revenue comes from SaaS, management is expanding its AI platform, and legendary investor John Paulson continues buying shares. We examine whether Wall Street is still valuing yesterday's business while tomorrow's company quietly takes shape.
🏦 Alkami Technology (ALKT): The “Picks and Shovels” of Digital Banking
Alkami Technology (ALKT) isn’t a bank — it’s the digital engine powering modern banking for millions of users. After a brutal fintech reset, General Atlantic just bought another $34M worth of shares. Coincidence… or conviction?
Sweetgreen (SG): 90% Down—Turnaround or Trap? 🥗📉
Sweetgreen looks fresh on the menu—but the stock tells a different story. With high short interest, insider buying, and weak fundamentals, SG is a high-risk contrarian bet investors should approach carefully.
Fundamental Research–Driven Fund Voss Capital Buys PAR Technology: Time to Shop?
PAR Technology is shifting from legacy hardware to a unified restaurant SaaS platform. After Voss Capital’s $7.1M buy, massive institutional ownership, and heavy short interest, the setup looks like an inflection-point story—high upside if execution clicks, sharp downside if it doesn’t.
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.
Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?
Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?
Could MGM Suddenly Stand for “My Great Money-Maker?”
Barry Diller is doubling down, insiders are buying, and MGM’s digital arm is gaining traction. Is the casino giant quietly becoming a global money machine again?
New CEO and Activist Corvex’s Keith Meister Buy Vestis; Expect Profits or Casual Tees?
A new CEO with UPS DNA, millions in insider buys, and activist hedge fund Corvex circling… Vestis stock checks many contrarian boxes. But high leverage and a slow turnaround mean this is not for the faint of heart. 👕📈